肿瘤细胞治疗研究
英文原题：Advances in adoptive cellular therapy for colorectal cancer: a narrative review.
尽管存在诸多障碍，ACT 在治疗结直肠癌方面仍展现出巨大前景。
背景与目的：近年来，过继细胞治疗（ACT）在抗肿瘤治疗中显示出巨大潜力。若要显著提高ACT治疗实体瘤的临床疗效，需要深入了解其最新进展。结直肠癌（CRC）是最常见的恶性肿瘤之一，严重威胁人类健康，也给全球医疗系统带来沉重负担。本文综述ACT治疗CRC的最新进展。方法：检索PubMed截至2022年8月31日发表的CRC过继细胞治疗相关文献，并从美国国立卫生研究院ClinicalTrials.gov网站获取相关临床试验信息；根据检索结果进行全面、系统的综述。主要内容与结果：本文介绍CRC过继细胞治疗研究进展，包括嵌合抗原受体（CAR）T细胞疗法、T细胞受体（TCR）工程化T细胞疗法和TIL（肿瘤浸润淋巴细胞）疗法，并介绍CRC CAR-T细胞临床试验中常见的肿瘤相关抗原（TAA）。结论：尽管存在诸多障碍，ACT治疗CRC仍很有前景。因此，有必要开展更多基础实验和临床试验，进一步明确ACT的有效性和安全性。
BACKGROUND AND OBJECTIVE: In recent years, adoptive cell therapy (ACT) has shown great potential in antitumor treatment. To significantly improve the clinical efficacy of ACT against solid tumors, we may need to carefully study the latest developments in ACT. As one of the most common malignancies, colorectal cancer (CRC) is a major risk to human health and has become a significant burden on global healthcare systems. This article reviews the recent advances in the treatment of CRC with ACT. METHODS: We searched PubMed for articles related to ACT for CRC published as of August 31, 2022, and retrieved relevant clinical trial information on the National Institutes of Health ClinicalTrials.gov website. Based on search results, comprehensive and systematic review is made. KEY CONTENT AND FINDINGS: This article provides an overview of the research progress of ACT for CRC, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR)-engineered T-cell therapy, and tumor-infiltrating lymphocyte (TIL) therapy. Common tumor-associated antigens (TAAs) in clinical trials of CAR-T cell therapy for CRC are described. CONCLUSIONS: Despite many obstacles, ACT shows great promise in treating CRC. Therefore, more basic experimental studies and clinical trials are warranted to further clarify the effectiveness and safety of ACT.
MEMBER ACCOUNT
登录成功会直接打开下一页。
